Europe plans IP waiver for pharma manufacturing
The European Commission plans to introduce a waiver to supplementary protection certificates (SPCs) to stimulate pharma manufacturing in Europe.
Archives for November 2, 2015
Shire buying Dyax for $5.9bn, but says Baxalta still a target
Shire’s acquisition of Dyax will add a Phase III mAb and an antibody generation technology, but the firm says it still has its eyes on Baxalta.